New concepts and insights into the role of radiation therapy in extracranial metastatic disease

References

• Hellman S, Weichselbaum RR. Oligometastases. J. Clin. Oncol. 13, 8–10 (1995).
   PubMed Web of Science ®Google Scholar
• Hellman S. Natural history of small breast cancers. J. Clin. Oncol. 12, 2229–2234 (1994).
   PubMed Web of Science ®Google Scholar
• Ksienski D, Woods R, Speers C et al. Patterns of referral and resection among patients with liver-only metastatic colorectal cancer (MCRC). Ann. Surg. Oncol. 17, 3085–3093 (2010).
   PubMed Web of Science ®Google Scholar
• Lo SS, Fakiris AJ, Teh BS et al. Stereotactic body radiation therapy for oligometastases. Expert Rev. Anticancer Ther. 9(5), 621–635 (2009).
   PubMed Web of Science ®Google Scholar
• Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M. Review and uses of stereotactic body radiation therapy in oligometastases. Oncologist 17(8), 1100–1107 (2012).
   PubMed Web of Science ®Google Scholar
• Tree AC, Khoo VS, Eeles RA et al. Stereotactic body radiation therapy for oligometastases. Lancet Oncol. 14, e28–e37 (2013).
   PubMed Web of Science ®Google Scholar
• Niibe I, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn. J. Clin. Oncol. 40(2), 107–111 (2010).
   PubMed Web of Science ®Google Scholar
• Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J. Clin. Oncol. 31, 1–8 (2013).
   PubMed Web of Science ®Google Scholar
• Fuks Z, Kolesnik R. Engaging the vascular component of the tumour response. Cancer Cell 8, 89–91 (2005).
   PubMed Web of Science ®Google Scholar
• Chmura SJ, Nodzenski E, Kharbanda S et al. Down-regulation of ceramide production abrogates ionizing radiation-induced cytochrome c release and apoptosis. Mol. Pharmacol. 57, 792–796 (2000).
   PubMed Web of Science ®Google Scholar
• Moeller BJ, Dreher MR, Rabbani ZN et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8(2), 99–110 (2005).
   PubMed Web of Science ®Google Scholar
• Reits EA, Hodge JW, Herberts CA et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumour immunotherapy. J. Exp. Med. 203(5), 1259–1271 (2006).
   PubMed Web of Science ®Google Scholar
• Lee Y, Auh SL, Wang Y et al. Therapeutic effects of ablative radiation on local tumour require CD8 T cells: changing strategies for cancer treatment. Blood 114(3), 589–595 (2009).
   PubMed Web of Science ®Google Scholar
• Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumours increases the generation of tumour antigen-specific effector cells that traffic to the tumour. J. Immunol. 174(12), 7516–7523 (2005).
   PubMed Web of Science ®Google Scholar
• Demaria S, Kawashima N, Yang AM et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11(2), 728–734 (2005).
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Barker CA et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366(10), 925–931 (2013).
   Web of Science ®Google Scholar
• McCammon R, Schefter TE, Gaspar LE et al. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 73(1), 112–118 (2009).
   PubMed Web of Science ®Google Scholar
• Zelefsky M, Greco C, Motzer R et al. Tumour control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 82(5), 1744–1748 (2012).
   PubMed Web of Science ®Google Scholar
• Stinauer MA, Kavanagh BD, Schefter TE et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat. Oncol. 6,34 (2011).
   PubMedGoogle Scholar
• Wulf J, Hadinger U, Oppitz U, Thiele W, Ness-Dourdomas R, Flentje M. Stereotactic radiotherapy of targets in the lung and liver. Stahlenther. Onkol. 177, 645–655 (2001).
   PubMed Web of Science ®Google Scholar
• Onimaru R, Shirato H, Shimizu S et al. Tolerance of organs at risk in small volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int. J. Radiat. Oncol. Biol. Phys. 56, 126–135 (2003).
   PubMed Web of Science ®Google Scholar
• Yoon SM, Choi EK, Lee SW et al. Clinical results of stereotactic body frame based fractionated radiation therapy for primary or metastatic thoracic tumours. Acta Oncol. 45, 1108–1114 (2006).
   PubMed Web of Science ®Google Scholar
• Okunieff P, Petersen AL, Philip A et al. Stereotactic body radiation therapy (SBRT) for lung metastases. Acta Oncol. 45, 808–817 (2006).
   PubMed Web of Science ®Google Scholar
• Norihisa Y, Nagata Y, Takayama K et al. Stereotactic body radiotherapy for oligometastatic lung tumours. Int. J. Radiat. Oncol. Biol. Phys. 72(2), 398–403 (2008).
   PubMed Web of Science ®Google Scholar
• Brown WT, Wu X, Fowler JF et al. Lung metastases treated by CyberKnife image-guided robotic stereotactic radiosurgery at 41 months. South. Med. J. 101, 376–382 (2008).
   PubMed Web of Science ®Google Scholar
• Rusthoven KE, Kavanagh BD, Burri SH et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J. Clin. Oncol. 27, 1579–1584 (2009).
   PubMed Web of Science ®Google Scholar
• Ricardi U, Filippi AR, Guarneri A et al. Stereotactic body radiation therapy for lung metastases. Lung Cancer 75(1), 77–81 (2012).
   PubMed Web of Science ®Google Scholar
• Wulf J, Haedinger U, Oppitz U, Thiele W, Mueller G, Flentje M. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int. J. Radiat. Oncol. Biol. Phys. 60, 186–196 (2004).
   PubMed Web of Science ®Google Scholar
• Filippi AR, Badellino S, Guarneri A et al. Outcomes of single fraction stereotactic ablative radiotherapy in lung metastases. Technol. Cancer Res. Treat. doi:10.7785/tcrt.2012.500355 (2013) ( Epub ahead of print).
   Google Scholar
• Greco C, Zelefsky MJ, Lovelock M et al. Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. Int. J. Radiat. Oncol. Biol. Phys. 79(4), 1151–1157 (2011).
   PubMed Web of Science ®Google Scholar
• Siva S, MacManus M, Ball D. Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J. Thorac Oncol. 5(7), 1091–1099 (2010).
   PubMed Web of Science ®Google Scholar
• Pastorino U, Buyse M, Friedel G et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J. Thorac Cardiovasc. Surg. 113(1), 37–47 (1997).
   PubMed Web of Science ®Google Scholar
• Widder J, Klinkenberg TJ, Ubbels JF, Wiegman EM, Groen HJ, Langendijk JA. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy? Radiother. Oncol. 107(3), 409–413 (2013).
   PubMed Web of Science ®Google Scholar
• Chawla S, Chen Y, Katz AW et al. Stereotactic body radiotherapy for treatment of adrenal metastases. Int. J. Radiat. Oncol. Biol. Phys. 75(1), 71–75 (2009).
   PubMed Web of Science ®Google Scholar
• Holy R, Piroth M, Pinkawa M, Eble MJ. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther. Onkol. 187, 245–251 (2011).
   PubMed Web of Science ®Google Scholar
• Torok J, Wegner RE, Burton SA, Heron DE. Stereotactic body radiation therapy for adrenal metastases: a retrospective review of noninvasive therapeutic strategy. Future Oncol. 7(1), 151–166 (2011).
   Web of Science ®Google Scholar
• Casamassima F, Livi L, Masciullo S et al. Stereotactic radiotherapy for adrenal gland metastases: University of Florence experience. Int. J. Radiat. Oncol. Biol. Phys. 82(2), 919–923 (2012).
   PubMed Web of Science ®Google Scholar
• Scorsetti M, Alongi F, Filippi AR et al. Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients. Acta Oncol. 51(5), 618–623 (2012).
   PubMed Web of Science ®Google Scholar
• Herfarth KK, Hof H, Bahner ML et al. Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumours. Int. J. Radiat. Oncol. Biol. Phys. 57, 444–451 (2003).
   PubMed Web of Science ®Google Scholar
• Hoyer M, Roed H, Traberg Hansen A et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 45, 823–830 (2006).
   PubMed Web of Science ®Google Scholar
• Kavanagh BD, Schefter TE, Cardenes HR et al. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol. 45, 848–855 (2006).
   PubMed Web of Science ®Google Scholar
• Mendez-Romero A, Wunderink W, Hussain SM et al. Stereotactic body radiation therapy for primary and metastatic liver tumours. Acta Oncol. 45, 831–837 (2006).
   PubMed Web of Science ®Google Scholar
• Lee MT, Kim JJ, Dinninwell R et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J. Clin. Oncol. 27, 1585–1591 (2009).
   PubMed Web of Science ®Google Scholar
• Rusthoven KE, Kavanagh BD, Cardenes H et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J. Clin. Oncol. 27, 1572–1578 (2009).
   PubMed Web of Science ®Google Scholar
• Goodman KA, Wiegner EA, Maturen KE et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int. J. Radiat. Oncol. Biol. Phys. 78, 486–493 (2010).
   PubMed Web of Science ®Google Scholar
• Rule W, Timmerman R, Tong L et al. Phase I dose escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann. Surg. Oncol. 18(4), 1081–1087 (2011).
   PubMed Web of Science ®Google Scholar
• Scorsetti M, Arcangeli S, Tozzi A et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int. J. Radiat. Oncol. Biol. Phys. 86(2), 336–342 (2013).
   PubMed Web of Science ®Google Scholar
• Choi C, Cho C, Yoo S et al. Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer. Int. J. Radiat .Oncol. Biol. Phys. 74, 147–153 (2009).
   PubMed Web of Science ®Google Scholar
• Jereczek-Fossa BA, Fariselli L, Beltramo G et al. Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother. Oncol. 93(1), 14–17 (2009).
   PubMed Web of Science ®Google Scholar
• Kim MS, Yoo SY, Cho CK et al. Stereotactic body radiotherapy for isolated para-aortic lymph node recurrence after curative resection in gastric cancer. J. Korean Med. Sci. 24, 488–492 (2009).
   PubMed Web of Science ®Google Scholar
• Kim MS, Cho CK, Yang KM, Lee DH, Moon SM, Shin YJ. Stereotactic body radiotherapy for isolated paraaortic lymph node recurrence form colorectal cancer. World J. Gastroenterol. 15, 6091–6095 (2009).
   PubMed Web of Science ®Google Scholar
• Casamassima F, Masi L, Menichelli C et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 97, 49–55 (2011).
   PubMed Web of Science ®Google Scholar
• Bignardi M, Cozzi L, Fogliata A et al. Critical appraisal of volumetric modulated arc therapy in stereotactic body radiation therapy for metastases to abdominal lymph nodes. Int. J. Radiat. Oncol. Biol. Phys. 75(5), 1570–1577 (2009).
   PubMed Web of Science ®Google Scholar
• Ryu S, Fang Yin F, Rock J et al. Image-guided and intensity-modulated radiosurgery for patients with spinal metastasis. Cancer 97, 2013–2018 (2003).
   PubMed Web of Science ®Google Scholar
• Chang EL, Shiu AS, Mendel E et al. Phase I/II study of stereotactic body radiotherapy for spinal metastases and its pattern of failure. J. Neurosurg. Spine 7, 151–160 (2007).
   PubMed Web of Science ®Google Scholar
• Gibbs IC, Kamnerdsupaphon P, Ryu MR et al. Image-guided robotic radiosurgery for spinal metastases. Radiother. Oncol. 82, 185–190 (2007).
   PubMed Web of Science ®Google Scholar
• Gerszten PC, Burton SA, Ozhasoglu C et al. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine 32, 193–199 (2007).
   PubMed Web of Science ®Google Scholar
• Yamada Y, Bilsky MH, Lovelock DM et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int. J . Radiat. Oncol. Biol. Phys. 71, 484–490 (2008).
   PubMed Web of Science ®Google Scholar
• Tsai JT, Lin JW, Chiu WT et al. Assessment of image-guided CyberKnife radiosurgery for metastatic spine tumours. J. Neuroncol. 94, 119–127 (2009).
   PubMed Web of Science ®Google Scholar
• Nguyen QN, Shiu AS, Rhines LD et al. Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 76, 1185–1192 (2010).
   PubMed Web of Science ®Google Scholar
• Milano MT, Katz AW, Muhs AG et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 112(3), 650–658 (2007).
   Web of Science ®Google Scholar
• Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int. J. Radiat. Oncol. Biol. Phys. 83(3), 878–886 (2011).
   PubMed Web of Science ®Google Scholar
• Salama JK, Hassella MD, Chmura SJ, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases. Cancer 118(11), 2962–2970 (2011).
   PubMedGoogle Scholar
• De Ruysscher D, Wanders R, van Baardwijk A et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases. Long term results of a prospective phase II trial (Nct01282450). J. Thorac Oncol. 7(10), 1547–1555 (2012).
   PubMed Web of Science ®Google Scholar
• Weickhardt AJ, Scheier B, Malachy Burke J et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J. Thorac Oncol. 7(12), 1807–1814 (2012).
   PubMed Web of Science ®Google Scholar
• Yu H, Sima CS, Huang J et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J. Thorac Oncol. 8(3), 346–351 (2103).
   Google Scholar
• Milano MT, Katz AW, Okunieff P et al. Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ. Am. J. Clin. Oncol. 33, 157–163 (2010).
   PubMed Web of Science ®Google Scholar
• Singh D, Yi WS, Brasacchio RA et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int. J. Radiat. Oncol. Biol. Phys. 58(1), 3–10 (2004).
   PubMed Web of Science ®Google Scholar
• Weichselbaum RR, Hellman S. Oligometastases revisited. Nat. Rev. Clin. Oncol. 8(6), 378–382 (2011).
   PubMed Web of Science ®Google Scholar
• Metha N, Mauer AM, Hellman S et al. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int. J. Oncol. 25, 1677–1683 (2004).
   PubMed Web of Science ®Google Scholar